Biotech Values

[oc631]

GILD still has the "simplest, safest, shortest, highly-effective interferon and ribavirin free" positioning which is all they need to dominate this market. The only way they can lose some of it is due to pricing/contracting competition.

GILD has the choice combo even before all the data reads out. However they will never dominate the GT1 market. The ABBV combo is highly competitive in this genotype even before price disparity is taken into consideration. I look at this as a special situation where ABBV has incredible leverage to set pricing which, in turn, will dictate their share of the GT1 market.